| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.28 | 8e-18 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-08 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-07 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.21 | 6e-06 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 6e-06 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.13 | 4e-05 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-05 |